Focal adhesion kinase-family-interacting protein of 200 kDa (FIP200) has been shown to regulate multiple cellular functions, including cell adhesion, autophagy, development and proliferation. Furthermore, FIP200 is considered to have tumor-suppressive activity, which may be correlated with its inactivation in human breast cancers, in addition to its role as an important signal transduction node. Herein, we report that FIP200 interacts with the oncoprotein b-catenin. Moreover, FIP200 promotes destabilization of wild-type b-catenin, but not a cancer-causing form of b-catenin, and as a result represses the b-catenin-mediated transcription. FIP200-induced degradation of b-catenin is independent of adenomatous polyposis coli (APC) of the well-established b-catenin destruction complex (glycogen synthase kinase-3b/axin/APC), in a component of b-catenin E3 ubiquitin ligase, b-TrCP-dependent manner. Thus, the APC-independent b-catenin degradation by FIP200 suggests a role for FIP200 in tumor suppression in the presence of APC dysfunction. These findings reveal a new and important function of FIP200 in regulation of the Wnt/b-catenin pathway.
INTRODUCTION
The oncogene b-catenin, which accumulates in many human cancers and induces the canonical Wnt signal pathway and proliferation, has a key role in the maintenance of embryonic, adult and cancer stem cells, as well as tumorigenesis. b-catenin has crucial roles in adhesion and Wnt signal transduction, which are critical in embryonic development and adult homeostatic regulation.
1,2 Wnts, extracellular glycoproteins, initiate the b-catenin/Wnt signaling cascade by binding and activating receptors in the b-catenin-dependent pathway. Activation of Wnt signaling results in accumulation of cytoplasmic b-catenin. 3 At elevated cytoplasmic levels, b-catenin translocates to the nucleus and co-operates with T-cell factor (TCF)/lymphocyte enhancer-binding factor (LEF) to activate the expression of the target genes. 3 In the absence of stimuli, b-catenin undergoes rapid turnover by a destruction complex, which contains axin, adenomatous polyposis coli (APC) and glycogen synthase kinase-3b (GSK-3b). 4 When bound to this destruction complex, b-catenin is phosphorylated by GSK-3b, thereby inducing its ubiquitination. This process is mediated by b-TrCP, and the subsequent degradation occurs through a proteasome-dependent pathway. 5, 6 In contrast, Wnt signals inhibit the GSK-3b-mediated phosphorylation of b-catenin, resulting in disassembly of the b-catenin destruction complex and an increase in b-catenin levels. 7 The importance of b-catenin in tumorigenesis is supported by discoveries of mutations in b-catenin and in components of the destruction complex in a wide variety of human cancers. 8, 9 It has been shown that 480% of colorectal cancers possess inactive mutants of the APC protein, which is correlated with increased levels of free b-catenin in cancer cells. 3 Somatic point mutations at the amino terminus of b-catenin, which alter the putative GSK-3b phosphorylation residues, have been reported in various types of cancers. 9 These mutations lead to an accumulation of stable b-catenin. Focal adhesion kinase-family-interacting protein of 200 kDa (FIP200) can function as an important signaling node to regulate diverse basic cellular processes, including adhesion, proliferation and survival/apoptosis. 10 FIP200 associates with Pyk2 11 and FAK, 12 thereby inhibiting their activities. FIP200 has also been shown to associate with the tuberous sclerosis complex and regulate its function. 13 Functional loss of FIP200 in mice leads to embryonic lethality, which is correlated with defective development and increased apoptosis. 14 FIP200 is also known as RB1-inducible coiled-coil 1, because it has been independently identified as a transcriptional inducer of the RB1 gene. 15 It functions in both the cytoplasm and the nucleus. A recent study has shown the spatial interplay of FIP200 with PIASy in the regulation of the tuberous sclerosis complex/S6K signal pathway in the cytoplasm and the PIASy/FIP200 transcriptional activity in the nucleus. 16 The FIP200 gene was identified by positional cloning from 8q11.2, a region that is frequently lost in human tumors. Thus, 10-20% of primary breast cancers were found to be associated with a dysfunction in FIP200, which has the features of a classical tumor suppressor, [17] [18] [19] suggesting the potential tumorsuppressing function of FIP200. Consistently, it is also a positive regulator of RB1 and p21 tumor suppressors, and thus it inhibits the cell-cycle progression and proliferation, thereby supporting its role in tumor suppression. In addition, FIP200 inhibits cell-cycle progression at the G1/S transition via p53 stabilization and cyclin D1 destabilization. 19 Lately, the function of FIP200 in autophagy is more highlighted and complicated regarding cancer biology. 20, 21 Recent studies have revealed that FIP200 interacts with ULK of autophagosomes and that it is required for autophagosome formation, downstream of the tuberous sclerosis complexmammalian target of the rapamycin (tuberous sclerosis complex-mTOR) pathway. 22 Furthermore, FIP200 can act as a cofactor for Arkadia E3 ubiquitin ligase, via modulating its ubiquitination activity, 23 supporting the plausible role of FIP200 in the regulation of protein degradation.
In this study, we provide evidence for an interaction between FIP200 and b-catenin. In addition, we suggest that the interaction between FIP200 and b-catenin reduces the level of b-catenin protein via proteasomal degradation of b-catenin. Moreover, FIP200 can function as a negative regulator of b-catenin/TCF/LEFmediated gene expression via destabilization of b-catenin.
RESULTS
Identification of FIP200 as a b-catenin-interacting protein To identify the molecular regulators of b-catenin, we screened a human lung library by using the yeast two-hybrid method with b-catenin as the bait. Importantly, some of the b-catenin-interacting clones perfectly matched the C-terminal sequence of the coding region of FIP200 ( Figure 1a ). The gene for human FIP200 encodes two alternatively spliced proteins composed of 1594 and 1591 amino-acid residues, which are called FIP200 transcript variant 1 and 2, respectively ( Figure 1b ). FIP200 transcript variant 2 is identical to FIP200 variant 1, except for the absence of amino-acid residues 1543-1545 (GEG) from the transcript (Figure 1b) . The clone DNA fragments that were identified as b-catenin-interaction partners in our study had the C-terminal region (amino acids 1279-1591) and a sequence of FIP200 transcript variant 2 (FIP200 CD) (Figures 1a and b ).
FIP200 interacts with b-catenin
To examine the association between b-catenin and the C-terminal fragment of the FIP200 C and CD in mammalian cells, coimmunoprecipitation was performed using extracts from 293T cells expressing SRT-tagged FIP200 C and CD and Flag-tagged b-catenin, which showed that Flag-tagged b-catenin co-precipitated with FIP200 C and CD ( Figure 1c ) in a manner similar to the b-catenin/APC/GSK-3b/axin complex (Supplementary Figure S1 ). This finding indicated that the C-terminal fragments of FIP200 interact with ectopically expressed b-catenin in mammalian cells.
To determine if the interaction of FIP200 with b-catenin is bona fide, we examined endogenous FIP200-b-catenin interaction. A co-immunoprecipitation experiment using the anti-FIP200 antibody showed that b-catenin was detected in the anti-FIP200 immunoprecipitates and vice versa (Figure 1d ). Together, these results indicate that endogenous FIP200-b-catenin interaction occurs in mammalian cells.
To determine b-catenin-interaction regions other than the FIP200 C or CD termini, we generated three additional truncated fragments with FIP200 N-terminal (N, 1-638), N-terminal and middle (N/M, 1-1278) and middle (M, 639-1278) regions (Figure 1b) , and tested the association between b-catenin and these FIP200 fragments from 293T cells in which various FIP200 fragments and FLAG-b-catenin were exogenously co-expressed (Figure 1e ). The co-immunoprecipitation experiments demonstrated that FLAG-b-catenin co-precipitates with all FIP200 fragments except FIP200 M (Figures 1c and e) . These results suggest that either the N or C terminus of FIP200 is sufficient for interaction with b-catenin.
The interaction of FIP200 with b-catenin occurred in the presence of lithium chloride, a GSK-3b inhibitor that mimics Wnt activation (Supplementary Figure S2) , in a manner similar to the interaction observed in the absence of Wnt signaling (Figure 1 ). This suggests that b-catenin and FIP200 interact in the Wnt pathway in a signal-independent manner.
Repression of b-catenin/TCF/LEF-mediated transcription by FIP200 To understand the functional role of this FIP200-b-catenin interaction, we investigated the effect of FIP200 on b-cateninmediated transcription. To this end, we evaluated the transcriptional activity of b-catenin/TCF/LEF by using a TCF/LEF-responsive luciferase (OT) and non-responsive (OF) reporter, which was regulated by b-catenin/TCF/LEF. b-catenin alone induced an approximately five-fold higher transcription from the b-catenin/ TCF/LEF-dependent promoter (OT) (Figure 2a We decided to further examine whether the transcriptional repression of the b-catenin/TCF/LEF-responsive promoter is a bona fide FIP200 activity and not an artifact of the ectopic expression of FIP200. To this end, we measured OT activity following small interfering RNA (siRNA) knockdown of FIP200 (Figure 2b ). In the FIP200-deficient cells without the ectopic expression of b-catenin, b-catenin/TCF/LEF-dependent transcription was 3.1-fold higher than the basal level. Moreover, the silencing of FIP200 synergistically induced b-catenin-mediated transcription in the presence of exogenously expressed b-catenin by approximately 18.2-fold, suggesting that FIP200 can physiologically regulate b-catenin-mediated transcription. FIP200 repressed b-catenin-mediated transcription in both Wnt-on (Supplementary Figure S4) and Wnt-off ( Figure 2 ) phases, which is consistent with the interaction pattern of FIP200 with b-catenin. (Figure 3a) . To confirm the effect of FIP200 on the level of b-catenin protein, we employed silencing vectors for targeting two different sequences of FIP200 mRNA (clone no. 1 and 2) to knockdown endogenous FIP200. The results revealed that FIP200 knockdown increased the level of b-catenin protein (Figure 3b ), indicating that FIP200 can downregulate the level of b-catenin protein.
To investigate whether FIP200 affects b-catenin protein stability, we monitored the degradation rate of b-catenin following cycloheximide (CHX) treatment. The level of b-catenin protein rapidly decreased in the presence of FIP200 CD, following CHX treatment (Figure 3c) . Moreover, the apparent half-life of b-catenin in the absence of FIP200 CD was approximately 2 h, whereas the half-life in the presence of FIP200 CD was approximately 1 h. The exogenous FIP200 CD induced destabilization of b-catenin when de novo synthesis of b-catenin was blocked by CHX treatment (Figure 3c ), suggesting that FIP200 can promote degradation of b-catenin. Together, our data describing b-catenin stability indicate that FIP200 can regulate the level of b-catenin by accelerating its degradation rate at the posttranslational level.
We further investigated whether the FIP200-mediated b-catenin destabilization is dependent on the proteasomal pathway. To this end, we compared the level and ubiquitination of b-catenin protein in the presence or absence of FIP200, following treatment with the proteasome inhibitor MG132 (Figures 3d and e) . Without regard to FIP200 expression, reductions in the b-catenin level were not observed when the cells were treated with MG132 (Figures 3d and e). However, some shifted bands for b-catenin were detected in the presence of FIP200 (Figure 3d ). Further, in the cells coexpressing FLAG-b-catenin and HA-ubiquitin, the ubiquitinated b-catenin proteins were more intensively detected with the HA or b-catenin antibody in the anti-FLAG immunoprecipitates in the presence of FIP200 F, N or C fragments (Figure 3e ). This result suggested that the FIP200 can induce the ubiquitination of b-catenin proteins. Two ubiquitin-binding motifs (UBMs) of FIP200 are required for the FIP200-mediated degradation of b-catenin protein To understand the molecular mechanism underlying the ubiquitination-dependent FIP200-induced degradation of b-catenin, we identified two potential UBMs 24, 25 in the FIP200 C terminus (Figure 4a ). First, we deleted each (FIP200 C-DUBM no. 1 or -DUBM no. 2) and both (FIP200 C-DUBM no. 1 þ 2) putative UBMs in the C-terminal fragment of FIP200 and then evaluated the effect of these UBM-deleted types of FIP200 on b-catenin protein levels. The binding of FIP200 to b-catenin was decreased by deletion of UBM no. 1, whereas it was not affected by deletion of UBM no. 2 in the FIP200 C terminus (Figure 4b ). Deletion of both UBMs in the FIP200 C terminus (FIP200 C-DUBM no. 1 þ 2) had little effect on the binding between the FIP200 C-terminal fragment and b-catenin. Further, the expression level of FIP200 C-DUBM no. 1, which appeared to bind weakly to b-catenin, was slightly lower in comparison with the wild-type or other deletion mutants ( Figure 4b) . Therefore, at present, the involvement of UBM no. 1 in the binding between FIP200 and b-catenin remains undetermined. However, the level of b-catenin protein was accumulated by FIP200 UBM mutants, in contrast to the decreased level of b-catenin in the presence of the wild-type of FIP200 in the C-terminal fragment ( Figure 4c ). These results suggest that UBMs may be required for the FIP200-induced destabilization of b-catenin. However, a functional connection between FIP200-mediated degradation and specific UBMs, ubiquitin-interacting motifs or ubiquitin-binding domains 26 Figure S5F ). Thus, we can speculate that the FIP200 N terminus may have more complicated structural features for ubiquitin binding or more than two ubiquitin-binding domains may work in combination.
To further clarify the importance of UBMs in FIP200 for degradation of b-catenin, an in vitro binding assay was performed with purified, glutathione S-transferase (GST)-tagged wild-type FIP200, UBM-deleted mutants of the FIP200 C-terminal fragment and 6 Â His-tagged mono-ubiquitin. As shown in Figure 4d , the amounts of ubiquitin bound to one or both UBM-deleted mutant types of FIP200 C (FIP200 C-DUBM no. 1, C-DUBM no. 2 and C-DUBM no. 1 þ 2) were lower than that bound with the wild-type FIP200 C. Further, the ubiquitin-binding activity of the FIP200 C-terminal fragment was dramatically reduced by deleting both UBMs (C-DUBM no. 1 þ 2)
To examine whether UBMs in FIP200 have a role in the ubiquitination of b-catenin, the level of ubiquitinated b-catenin was measured in the presence of wild-type and UBM-deleted mutants of the FIP200 C-terminal fragment (Figure 4e ). UBMdeleted mutants of the FIP200 C-terminal fragment induced a reduction in ubiquitinated b-catenin proteins, in comparison with that in the presence of the wild-type FIP200 C (Figure 4e ), which implied that UBMs are physiologically important for ubiquitination of b-catenin. Taken together, these experiments with UBM-deleted FIP200 types suggest that UBMs in FIP200 have a role in the FIP200-mediated degradation of b-catenin. Next, we examined whether UBMs in FIP200 are functionally linked to the FIP200-induced repression of b-catenin-mediated transcription. To this end, we evaluated b-catenin/TCF/LEFmediated transcriptional activity by using the UBM-deleted FIP200 C-terminal mutant fragments. In contrast to the wild-type FIP200 C, either one or both UBM-deleted mutants had little effect on b-catenin/TCF/LEF-responsive promoter-driven transcription (Figure 4f ). These findings indicate that UBMs in the FIP200 C terminus are required for the repression of the b-catenin/TCF/LEFmediated transcriptional activity by promoting the degradation of b-catenin.
FIP200 destabilizes endogenous b-catenin proteins in colorectal cancer cells, in an adenomatous polypopsis coli (APC)-independent manner To understand the physiological significance of FIP200 in the regulation of b-catenin, we next examined the effect of FIP200 on GST-tagged WT, one or both UBMs-deleted FIP200 C-terminal mutants (D1, D2 or D1 þ 2), and GST proteins were immobilized on GST Sepharose beads and incubated with 3 Â histidine-tagged ubiquitin (His-Ub) proteins. His-Ub proteins that were bound to the immobilized GST (#) or GST-FIP200 protein (*) were analyzed via Ponceau S staining and immunoblotting with the anti-Ub antibody (IB: Ub). Equal amount of GST-WT, one or both UBMs-deleted FIP200 C-terminal mutant (D1, D2, or D1 þ 2) proteins (*), used for the in vitro interaction assay were confirmed by Coomassie blue staining. (e) FIP200 C-terminal UBMs promote b-catenin ubiquitination. The 293T cells transfected with expression plasmids for HA-ubiquitin, either FIP200 C-terminal WT, D1, D2 or D1 þ 2, were treated with 10 mM MG132. After 6 h, the cellular lysates were analyzed via immunoblot using the anti-b-catenin antibody. (f ) Deletion of UBMs abolished the FIP200-induced inhibition of b-catenin/TCF/LEF-mediated transcription. b-catenin/TCF/LEF-responsive transcription reporter activity was measured in the presence of FIP200 C-terminal WT or UBM deletion mutants. using the anti-b-catenin antibody (Figure 5b) . Further, the decrease in b-catenin was observed mainly in the nuclear fraction of SW480 cells and was considerably less in the cytoplasmic fraction, whereas FIP200 mediated the degradation of both nuclear and cytoplasmic b-catenin in HCT116 cells (Figure 5a and Supplementary Figure S6) . To further confirm the APC independence of FIP200-induced b-catenin degradation, we depleted 293T cells of endogenous APC with siRNAs specific for APC mRNA. APC-depleted cells exhibited a decreased level of endogenous and exogenous b-catenin following FIP200 expression (Figure 5c ). Taken together, these results suggested that the effect of FIP200 on the stability of b-catenin protein is independent of the presence of APC.
Next, we assessed the effect of FIP200 on b-catenin/TCF/LEFmediated transcription in colon cancer cells. FIP200 expression reduced transcription of the b-catenin/TCF/LEF-responsive promoter in both HCT116 and SW480 cells (Figure 5d ). To further examine whether the transcriptional repression of b-catenin/TCF/ LEF-target genes is a bona fide FIP200 activity and not an artifact of the reporter assay, we measured the levels of cyclin D1 and (Figure 5d ), indicating that FIP200 can physiologically regulate the b-cateninmediated transcription. Together, our data for colon cancer cells provides evidence that FIP200 interacts with b-catenin, and as a result, it destabilizes b-catenin and suppresses b-catenin/TCF/LEFmediated transcription in an APC-independent manner. FIP200-mediated degradation of b-catenin, without regard to autophagy stimulus Recent studies have raised the possibility that autophagy can negatively regulate Wnt/b-catenin signaling. 27, 28 Because FIP200 has an essential role in the initial stages of autophagy, 22, 29 we examined whether FIP200 may regulate b-catenin degradation through its autophagy function. Thus, we first investigated whether induction and/or inhibition of autophagy has any effect on FIP200-mediated b-catenin degradation. Two autophagy stimuli, the mTOR inhibitor rapamycin (Figure 6a ) and nutrient deprivation (Figure 6b ), decreased b-catenin protein to a level almost equal to or marginally less than that found in cells ectopically expressing FIP200. The reduced b-catenin level was rescued upon inhibition of autophagy by both 3-methyladenine Figure S7A) . However, the b-catenin degradation induced by autophagy stimuli alone was sensitive to autophagy inhibitor but not to MG132 (Supplementary Figure S7B) . Similarly, the decreased level of b-catenin upon overexpressing FIP200 was rescued by MG132 but not autophagy inhibitor (Supplementary Figure S7C) . These restoration data obtained using autophagy or a proteasome inhibitor suggest that FIP200 regulates b-catenin degradation via a pathway that is distinct from autophagy. This supposition was supported by the differential degradation pattern of Wnt signaling proteins in autophagy-and FIP200-mediated b-catenin degradation processes. Consistent with previous reports, autophagy downregulates both b-catenin and Dvl2 proteins 27 (Supplementary Figure S7D) . However, rapamycin had little effect on the FIP200 level (Supplementary Figure S7D,  left panel) . Additionally, depletion of the FIP200 protein by siRNA caused the upregulation of b-catenin proteins but not alteration of Dvl2 and pLRP6 (Supplementary Figure S7D, right panel) . These observations indicated that autophagy induces degradation of b-catenin by promoting Dishevelled (including Dvl2) degradation but not regulating FIP200 proteins (Supplementary Figure S7D) , and degradation of Dvl2 is not required for the FIP200-mediated b-catenin degradation (Supplementary Figure S7D) , indicating that the FIP200-mediated b-catenin degradation may involve a pathway separate from autophagy.
To further examine whether FIP200 regulates degradation of b-catenin via its other function rather than autophagy, we employed silencing of ULK1, one of the key components of the autophagy ULK1-Atg13-FIP200 complex. 29 We monitored the level of b-catenin protein in ULK1-knockdown cells in the presence or absence of rapamycin. Silencing of ULK1 or FIP200 inhibited autophagy in a comparable manner (Figure 6c) . However, silencing of ULK1 had little effect on the level of b-catenin, which was in contrast to remarkable increase of b-catenin by silencing of FIP200 (Figure 6c) . Regardless of autophagy stimulus (rapamycin), b-catenin protein was noticeably increased in the FIP200-knockdown but not in the ULK1-knockdown cells (Figure 6c) . Similarly, Baf (Figure 6d ) or 3-MA (Supplementary Figure S7E) blocked autophagy but did not affect the increased level of b-catenin induced by FIP200 silencing. Taken together, these data suggest that FIP200 can regulate the stability of b-catenin protein regardless of autophagy.
DISCUSSION
In this study, we present, for the first time, data indicating a link between FIP200 and the b-catenin/Wnt signal pathway, thus supporting the significance of this interaction in the crossroads of diverse signal transduction pathways. FIP200 interacted with b-catenin and downregulated b-catenin-mediated transcription by promoting b-catenin ubiquitination in an APC-independent manner. Further, the results of this study point toward a novel molecular mechanism in which FIP200 may participate in tumor suppression and development by controlling the stability of b-catenin. The results also suggest that UBMs in the FIP200 C and possibly N termini have a role in directing the degradation of b-catenin. FIP200 can act as an adapter to link target proteins, including b-catenin, to the proteasome-dependent degradation pathway.
Initially, FIP200 was proposed as a potential tumor suppressor when its mutations were analyzed in human breast cancer tissues. 15 Furthermore, FIP200 has been implicated in various cellular processes, including development, differentiation and tumor suppression, 10, 30, 31 although the molecular mechanisms by which FIP200 participates in development and tumorigenesis have not been fully elucidated. Nonetheless, recent research using deletion of FIP200 in conditional knockout mouse models has shown that FIP200-mediated autophagy has an oncogenic effect on oncogene-induced breast cancer. 20 Contrary to the data from conditional knockout mouse models, FIP200 appears to function, by positive or negative control, in the regulation of diverse types of important tumor suppressor and oncogenic proteins via regulation of protein stability. 19, 32 These processes result in both inhibition of cell-cycle progression and proliferation and promotion of DNA-damage response and cell death. Consistent with these findings, our data show that FIP200 interacts with and promotes the ubiquitin-mediated degradation of b-catenin, thereby inhibiting the oncogenic function of b-catenin. This suggests the possible function of FIP200 in tumor suppression through governing the protein-degradation pathway. According to the current literature and experimental evidence, it appears that FIP200 has a more complex dual role in carcinogenesis and tumor suppression. Through a broad spectrum of interdependent interactions, FIP200 can act as an oncogenic factor or tumorsuppressive factor depending on the stage of tumor initiation, progression and metastasis. FIP200 can act as an ubiquitination adaptor for the selective degradation pathway via its UBMs and interaction with target proteins. b-catenin is one of the well-characterized oncoproteins that is highly expressed and stabilized in various cancers. 33 In this regard, tight regulation of b-catenin level is important in normal cellular physiology. In cancer cells, mutations affecting the regulation of b-catenin levels can result in increasing the cellular level of b-catenin, which is considered to be a key event in tumorigenesis. Negative regulators of b-catenin target its degradation mechanisms. For instance, APC, a well-known tumor suppressor, promotes degradation of b-catenin through the APC/ axin destruction complex or a p53-inducible pathway involving Siah-1 in the proteasomal degradation pathway. 34 In addition, other APC-independent pathways have been suggested to regulate the cellular level of b-catenin. [35] [36] [37] In this study, we observed that overexpression of FIP200 reduces the level of b-catenin in SW480 cells. Given that FIP200 has previously been shown to inhibit the proliferation of human tumor cells, it would be interesting to further investigate whether the inhibitory role of FIP200 in cell growth is mediated through the regulation of b-catenin.
One of the mechanisms for the diverse cellular functions of FIP200 may be mediated through the regulation of protein stability in a proteasomal degradation-dependent manner. FIP200 induces p53 stabilization, cyclin D1 destabilization and autophagy. These results are consistent with the FIP200-induced degradation of b-catenin in our data. These selective degradation pathways mediated by FIP200, including the FIP200-induced degradation of b-catenin identified in this work, can impose molecular quality control of aberrant proteins or unbalanced protein levels. The FIP200-induced destabilization of b-catenin is closely associated with a strong increase in ubiquitination. Moreover, two identified UBMs in C-terminal FIP200 are required for promoting the degradation of b-catenin, implying its role as an adaptor in protein degradation. Consistent with our data, a recent study has shown that FIP200 acts as a scaffold/cofactor protein for the E3 ligase, Arkadia, which ubiquitinates c-Ski and SnoN. 23 Therefore, in the detailed mechanism, the ubiquitin-binding domains in FIP200 may have a crucial role in ubiquitinating target proteins.
Although FIP200 was able to interact with the APC/axin destruction complex (Figure 1, Supplementary Figure S1 ) and cancer-causing b-catenin (S33Y) mutant (Supplementary Figure  S8) , it had little effect on the degradation of non-phosphorylated b-catenin (S33Y) mutant (Figure 3c, Supplementary Figure S9 ). In addition, FIP200 could not exert an influence on the phosphorylation of b-catenin (Supplementary Figure S10) . These results suggest that the FIP200-induced degradation of b-catenin is dependent on GSK-3b-mediated phosphorylation. b-TrCP is an E3 ubiquitin ligase adaptor and is a key stability regulator for phosphorylated b-catenin.
5 FIP200 can interact with b-TrCP (Supplementary Figure S11) but not with Siah-1 (data not shown), showing that FIP200 destabilizes b-catenin, via association with bTrCP, in an ubiquitination-dependent manner (Supplementary Figure S12) . It is not clear whether the effect of FIP200 on protein stability is limited to b-catenin or whether it generally affects the degradation of other b-TrCP substrates. Further, involvement of the FIP200 UBMs in this process is entirely unknown. The requirement of UBMs for ubiquitination suggests that they might act as adaptors for connecting other substrates to b-TrCP. To increase our knowledge regarding the molecular function of UBMs in FIP200, it would be important to further investigate whether the identified UBMs can be implicated in regulating the stability of other proteins, including b-TrCP or other E3 ligase target proteins.
Whether and how FIP200 has a role in tumorigenesis is still controversial, for all its deletion in human breast cancers and its function in controlling the level of proteins implicated in oncogenesis and tumor suppression. Neither is it known whether FIP200 functions as a tumor suppressor, because mice knocked out for the FIP200 gene do not develop tumors, with a much higher or severer incidence, 38 and the FIP200-mediated Regulation of b-catenin stability by FIP200 JD Choi et al autophagy can be critical in oncogene-induced mammary tumorigenesis. 20 The embryonic fibroblasts of FIP200-deficient mice showed significant defects in DNA-damage repair and cell survival. 21 Thus, a better understanding of FIP200 function in tumorigenesis is still needed.
In addition to b-TrCP-or Siah-1-mediated degradation of bcatenin, it is reported that Jade-1 can destabilize b-catenin in both Wnt-on/off phases to maintain homeostasis of b-catenin protein at the cellular level. 39 Moreover, recent reports suggest that autophagy downregulates b-catenin protein. 27, 28 In this work, we propose FIP200 as a novel negative regulator of b-catenin, which acts in a distinct pathway. FIP200 has a dual role in the downregulation of b-catenin: as a scaffold for ubiquitinationmediated degradation and as an autophagy signaling transducer as a component of the ULK1 complex. Noticeably, FIP200 can negatively regulate the stability of b-catenin in the absence of autophagy stimuli ( Figure 6 and Supplementary Figure S7) or Wnt signaling (Supplementary Figure S4) .
In this study, we demonstrate that FIP200 promotes APCindependent b-catenin ubiquitination and that this leads to the repression of b-catenin-mediated transcription. FIP200 induces degradation of b-catenin in colon cancer cells (Supplementary Figure S6 ) and efficiently represses b-catenin-mediated transcription. The findings of this study thus provide evidence for novel liaisons among Wnt and other FIP200-linked signal pathways.
MATERIALS AND METHODS
Yeast two-hybrid screen Yeast two-hybrid screening was carried out according to the manufacturer's protocol (Clontech, Mountain View, CA, USA). A cDNA library from human lung tissues in pACT2 (Clontech) was screened for human b-catenin (a gift from B Vogelstein, Johns Hopkins University) by using the pGBKT7 vector. Constructs for b-catenin in pLexA (Clontech; pLexA-b-catenin) and the C terminus of FIP200 (1278-1591) in pB42AD (pB42AD-FIP200 CD) were generated and used to confirm the interaction of b-catenin and FIP200 in the yeast strain EGY48 (Clontech). Yeast strain EGY48 was cotransformed with pLexA-b-catenin and pB42AD-FIP200 CD and grown on selective media containing X-Gal (5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside; Clontech). The blue colonies on the selective media indicated a positive interaction.
Plasmid construction
The mammalian expression vectors for full-length and truncated FIP200 DNA were generated by PCR using IMAGE clones (MHS1010-73933; Thermo Fisher Scientific Open Biosystems, Huntsville, AL, USA) with a pcDNA3 vector (Invitrogen, Carlsbad, CA, USA) hooked to the SRT epitope. Constitutively active cancer-causing b-catenin protein (S33Y) carrying a substitution of serine (codon 33) by tyrosine, with an amino-acid substitution at the GSK-3b phosphorylation site in the FLAG-pcDNA3 vector, were generated using a QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA). Double-stranded siRNAs for FIP200, APC and b-TrCP were generated using the pSUPER vector. 40 The sequences used for siRNA are as follows: FIP200 (Clone no. Cell cultures, transfection and treatment Human 293T, HCT116 and SW480 cell lines were cultured in DMEM, RPMI and L-15 medium, respectively, supplemented with 10% fetal calf serum (HyClone, Denver, CO, USA). DNA transfection experiments were conducted using the Effectene Transfection Kit (Qiagen, Carlsbad, CA, USA) or Fugene HD (Promega, Madison, WI, USA) according to the manufacturer's instructions. Prior to harvesting, the cells were treated with 10 mM proteasome inhibitor MG132 (CalBiochem, San Diego, CA, USA) for 6 h, 100 mg/ml CHX (Sigma-Aldrich, Saint Louis, MO, USA) for the indicated times, 10 mM 3-MA (Sigma-Aldrich) for 12 h or 100 nM Baf (Sigma-Aldrich) for 12 h. For autophagy induction, 293T cells were incubated for 6 h in DMEM containing 2-4 mM rapamycin or in Hanks' balanced salt solution (Invitrogen).
Immunoblotting and co-immunoprecipitation
Immunoblotting and co-immunoprecipitation were performed as described, 40 using the anti-FLAG M2, anti-ULK1 (Sigma-Aldrich), anti-SRT (Genecode, Korea), anti-HA (COVANCE, Princeton, NJ, USA), anti-FIP200, anti-APC, anti-Lamin B (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-b-catenin, anti-a-tubulin (Millipore, Billerica, MA, USA), antiphosphorylated b-catenin at Ser33/Ser37/Thr41, anti-phosphorylated LRP6 at Ser1490, anti-Dvl2 (Cell Signaling Technology, Danvers, MA, USA), anti-LC3B (Sigma-Aldrich), and anti-Ubiquitin (Zymed, South San Francisco, CA, USA) primary antibodies, and species-specific secondary antibodies (Zymed).
Reporter assay A reporter assay was performed as described previously 41, 42 using the reporter construct Topflash (pGL3-OT) and Fopflash (pGL3-OF) (gifts from B Vogelstein), an internal control Renilla luciferase reporter (Promega), and the indicated plasmid.
Total RNA preparation and real-time PCR Total cellular RNA was isolated from cells using an RNeasy mini kit according to the manufacturer's protocol (Qiagen). Quantitative RT-PCR was performed using SYBR premix Ex taq (Takara Bio, Shiga, Japan). . For quantification, all the values were normalized to that of b-actin (for quantitative RT-PCR) using the DDCt method from three to five independent experiments. All quantitative PCRs were analyzed using the TP800 Thermal Cycler Dice Real Time System (Takara).
In vitro binding assay
The expression and purification of GST fusion proteins and GST pull-down assays were carried out as described previously. 43 Briefly, following the separate incubation of approximately equal amounts of purified GSTfusion wild-type FIP200 and UBM-deleted mutant proteins mixed with histidine-tagged recombinant ubiquitin (Boston BioChem, Boston, MA, USA) in the presence of glutathione sepharose 4B beads (GE healthcare, Piscataway, NJ, USA), the bound proteins were probed with Ponceau S (Sigma-Aldrich) and anti-Ub antibody (Zymed).
Immunofluorescence
The HCT116 and SW480 cells were strained with the appropriate primary antibodies, followed by incubation with Alexa488-or Alexa594-conjugated secondary antibodies (Invitrogen). The cell nuclei were stained with 4',6-diamidino-2-phenylindole. The samples were analyzed under an LSM700 confocal laser scanning microscope (Carl Zeiss, Thornwood, NY, USA).
